Article 26 Transitional provision
United Kingdom
The Member States may continue to apply national transposition measures adopted under Commission Directive 2003/94/ECf1 to the manufacture of investigational medicinal products used in clinical trials governed by Directive 2001/20/EC of the European Parliament and of the Councilf2 in accordance with the transitional provisions laid down in Article 98 of Regulation (EU) No 536/2014.
Annotations
Footnotes
- f1
-
Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use (OJ L 262, 14.10.2003, p. 22).
- f2
-
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (OJ L 121, 1.5.2001, p. 34).